Malignant Lung Neoplasm — Trials

Malignant Lung Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

11,125 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,650
Recruiting: 1,432
Ph III recruiting: 179
Growth YoY: +7%
Industry share: 37%
Top sponsor: AstraZeneca
Termination share: 34.8%
Trials / 1,000 deaths: 20.1 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,491)

clinicaltrialsPublishedShowing 301–350 of 3,333 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06899126	Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer(DESTINY-Lung06)	recruiting	Phase 3	686	Daiichi SankyoINDUSTRY	23	Sep 15, 2026	clinicaltrials
NCT07061535	Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer(STAR-SCLC)	recruiting	Phase 2	40	Second Affiliated Hospital, Zhejiang University, School of Medicine